MCID: URT030
MIFTS: 32

Ureteral Benign Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Ureteral Benign Neoplasm

MalaCards integrated aliases for Ureteral Benign Neoplasm:

Name: Ureteral Benign Neoplasm 12 15
Neoplasm of Ureter 12
Ureteral Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11885
MeSH 45 D014516
NCIt 51 C3427
UMLS 74 C0041955

Summaries for Ureteral Benign Neoplasm

MalaCards based summary : Ureteral Benign Neoplasm, also known as neoplasm of ureter, is related to horseshoe kidney and ureter, cancer of. An important gene associated with Ureteral Benign Neoplasm is GCM2 (Glial Cells Missing Transcription Factor 2), and among its related pathways/superpathways are Neuroscience and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and endothelial, and related phenotypes are Reduced mammosphere formation and nervous system

Related Diseases for Ureteral Benign Neoplasm

Diseases related to Ureteral Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 horseshoe kidney 29.7 CHGA ENO2 KRT7 NKX2-1 SYP
2 ureter, cancer of 11.5
3 ureter leiomyoma 11.3
4 regional ureteric cancer 11.1
5 kidney benign neoplasm 11.1
6 central nervous system primitive neuroectodermal neoplasm 10.5 ENO2 SYP
7 melanotic neuroectodermal tumor 10.5 ENO2 SYP
8 cerebral ventricle cancer 10.5 ENO2 SYP
9 cerebral neuroblastoma 10.5 ENO2 SYP
10 cerebellum cancer 10.5 ENO2 SYP
11 extraosseous chondrosarcoma 10.5 ENO2 SYP
12 subependymal glioma 10.5 ENO2 SYP
13 benign ependymoma 10.5 ENO2 SYP
14 pineal gland cancer 10.5 ENO2 SYP
15 clear cell ependymoma 10.5 ENO2 SYP
16 malignant teratoma 10.5 ENO2 SYP
17 astroblastoma 10.5 ENO2 SYP
18 prostate small cell carcinoma 10.5 ENO2 NKX2-1
19 urethral benign neoplasm 10.5 CHGA UPK3A
20 chronic cystitis 10.5 KRT7 UPK3A
21 acute thyroiditis 10.5 CHGA ENO2
22 olfactory groove meningioma 10.5 CHGA SYP
23 seminal vesicle tumor 10.5 KRT7 SYP
24 medulloepithelioma 10.5 KRT7 SYP
25 glycogen-rich clear cell breast carcinoma 10.5 KRT7 SYP
26 papillary serous adenocarcinoma 10.5 KRT7 NKX2-1
27 papillary adenoma 10.5 KRT7 NKX2-1
28 pancreatic endocrine carcinoma 10.5 NCAM1 SYP
29 supratentorial primitive neuroectodermal tumor 10.5 NCAM1 SYP
30 middle cerebral artery infarction 10.5 ENO2 NCAM1
31 mediastinal cancer 10.5 NCAM1 SYP
32 carotid body cancer 10.5 ENO2 SYP
33 malignant sertoli cell tumor 10.5 ENO2 SYP
34 ureter small cell carcinoma 10.4 CHGA SYP
35 renal pelvis transitional cell carcinoma 10.4 KRT7 UPK3A
36 epithelial predominant wilms' tumor 10.4 KRT7 NCAM1
37 sinonasal undifferentiated carcinoma 10.4 ENO2 SYP
38 ovary neuroendocrine neoplasm 10.4 KRT7 SYP
39 intracranial primitive neuroectodermal tumor 10.4 CHGA ENO2
40 acinar cell cystadenocarcinoma 10.4 CHGA SYP
41 multiple mucosal neuroma 10.4 ENO2 NCAM1
42 pancreatic somatostatinoma 10.4 ENO2 SYP
43 glandular cystitis 10.4 KRT7 UPK3A
44 peritoneal serous adenocarcinoma 10.4 CHGA SYP
45 cellular ependymoma 10.4 CHGA SYP
46 lung combined type small cell carcinoma 10.4 NCAM1 SYP
47 papillary tumor of the pineal region 10.4 ENO2 SYP
48 primary hepatic neuroendocrine carcinoma 10.4 CHGA SYP
49 papillary transitional carcinoma 10.4 ENO2 KRT7
50 solid adenocarcinoma with mucin production 10.4 KRT7 NKX2-1

Graphical network of the top 20 diseases related to Ureteral Benign Neoplasm:



Diseases related to Ureteral Benign Neoplasm

Symptoms & Phenotypes for Ureteral Benign Neoplasm

GenomeRNAi Phenotypes related to Ureteral Benign Neoplasm according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD1A CHGA ERBB3 FOXO4 GART KRT7

MGI Mouse Phenotypes related to Ureteral Benign Neoplasm:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 ARPP21 CHGA ENO2 ERBB3 GCM2 GRP

Drugs & Therapeutics for Ureteral Benign Neoplasm

Drugs for Ureteral Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
8
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
10
Pemetrexed Approved, Investigational Phase 3,Phase 2 150399-23-8, 137281-23-3 60843 446556
11
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
13
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
15
Bevacizumab Approved, Investigational Phase 3 216974-75-3
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
18
Doxil Approved June 1999 Phase 3,Phase 1,Phase 2 31703
19
Cobalamin Experimental Phase 3 13408-78-1 6857388
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Immunologic Factors Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
28 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
29 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
31 Vitamin B Complex Phase 3,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2
34 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
35 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
36 Vitamin B9 Phase 3,Phase 2
37 Folate Phase 3,Phase 2
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
39 Dermatologic Agents Phase 3,Phase 2
40 Antirheumatic Agents Phase 3,Phase 2
41 Folic Acid Antagonists Phase 3,Phase 2
42 Antibodies Phase 3,Phase 2,Phase 1
43 Immunoglobulins Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
45 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
46 Vitamin B 12 Phase 3
47 Hematinics Phase 3
48 HIV Protease Inhibitors Phase 3
49 Anti-Inflammatory Agents Phase 3
50 Vitamins Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
2 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
3 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
4 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
5 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
6 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
7 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
8 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
9 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
10 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
11 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
12 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
13 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
14 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
15 Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00101608 Phase 2 vinflunine
16 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
17 Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer Completed NCT00041106 Phase 2 gemcitabine hydrochloride;cisplatin;gefitinib
18 Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer Completed NCT00792025 Phase 2 sunitinib malate
19 Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00310011 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
20 Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract Completed NCT00112671 Phase 2 sorafenib tosylate
21 R115777 in Treating Patients With Advanced Bladder Cancer Completed NCT00006376 Phase 2 chemotherapy;tipifarnib
22 Oxaliplatin in Treating Patients With Metastatic Bladder Cancer Completed NCT00004203 Phase 2 oxaliplatin
23 Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter Completed NCT00066352 Phase 2 bortezomib
24 Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer Completed NCT00028860 Phase 2 carboplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
25 Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer Completed NCT00003105 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide;paclitaxel
26 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
27 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
28 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
29 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
30 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
31 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
32 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Completed NCT00003175 Phase 2 fluorouracil
33 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
34 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
35 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
36 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
37 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2 gefitinib
38 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2 irinotecan hydrochloride
39 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
40 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
41 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
42 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
43 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
44 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
45 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
46 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed NCT00021099 Phase 2 ixabepilone
47 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
48 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
49 Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms Recruiting NCT02430779 Phase 1, Phase 2
50 LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Recruiting NCT02612194 Phase 2 Crizotinib

Search NIH Clinical Center for Ureteral Benign Neoplasm

Genetic Tests for Ureteral Benign Neoplasm

Anatomical Context for Ureteral Benign Neoplasm

MalaCards organs/tissues related to Ureteral Benign Neoplasm:

42
Kidney, Bone, Endothelial

Publications for Ureteral Benign Neoplasm

Articles related to Ureteral Benign Neoplasm:

# Title Authors Year
1
Primary benign neoplasm of ureter associated with ureteral calculus. ( 12991398 )
1952

Variations for Ureteral Benign Neoplasm

Expression for Ureteral Benign Neoplasm

Search GEO for disease gene expression data for Ureteral Benign Neoplasm.

Pathways for Ureteral Benign Neoplasm

Pathways related to Ureteral Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 ENO2 NCAM1 NKX2-1 SYP
2 10.86 CEACAM5 GP5 NCAM1

GO Terms for Ureteral Benign Neoplasm

Biological processes related to Ureteral Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 8.62 CHGA GRP

Sources for Ureteral Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....